William A Stokes1, David C Binder2, Bernard L Jones3, Ayman J Oweida4, Arthur K Liu5, Chad G Rusthoven6, Sana D Karam7. 1. Department of Radiation Oncology, University of Colorado Denver School of Medicine, Aurora, CO, USA. Electronic address: william.stokes@ucdenver.edu. 2. Department of Radiation Oncology, University of Colorado Denver School of Medicine, Aurora, CO, USA. Electronic address: david.binder@ucdenver.edu. 3. Department of Radiation Oncology, University of Colorado Denver School of Medicine, Aurora, CO, USA. Electronic address: bernard.jones@ucdenver.edu. 4. Department of Radiation Oncology, University of Colorado Denver School of Medicine, Aurora, CO, USA. Electronic address: ayman.oweida@ucdenver.eduu. 5. Department of Radiation Oncology, University of Colorado Denver School of Medicine, Aurora, CO, USA. Electronic address: arthur.liu@ucdenver.edu. 6. Department of Radiation Oncology, University of Colorado Denver School of Medicine, Aurora, CO, USA. Electronic address: chad.rusthoven@ucdenver.edu. 7. Department of Radiation Oncology, University of Colorado Denver School of Medicine, Aurora, CO, USA. Electronic address: sana.karam@ucdenver.edu.
Abstract
BACKGROUND: Patients with melanoma brain metastases (MBM) have been excluded from trials evaluating immunotherapy in melanoma. As such, immunotherapy's role in MBM is poorly understood, particularly in combination with radiotherapy. METHODS: The National Cancer Database was queried for patients with MBM receiving brain radiotherapy. They were classified according to immunotherapy receipt. Multivariate Cox regression was performed to identify factors associated with survival. RESULTS: Among 1287 patients, 185 received immunotherapy. Factors associated with improved survival included younger age, academic facility, lower extracranial disease burden, stereotactic radiotherapy, chemotherapy, and immunotherapy. CONCLUSIONS: Adding immunotherapy to radiotherapy for MBM is associated with improved survival.
BACKGROUND:Patients with melanoma brain metastases (MBM) have been excluded from trials evaluating immunotherapy in melanoma. As such, immunotherapy's role in MBM is poorly understood, particularly in combination with radiotherapy. METHODS: The National Cancer Database was queried for patients with MBM receiving brain radiotherapy. They were classified according to immunotherapy receipt. Multivariate Cox regression was performed to identify factors associated with survival. RESULTS: Among 1287 patients, 185 received immunotherapy. Factors associated with improved survival included younger age, academic facility, lower extracranial disease burden, stereotactic radiotherapy, chemotherapy, and immunotherapy. CONCLUSIONS: Adding immunotherapy to radiotherapy for MBM is associated with improved survival.
Authors: Norbert Galldiks; Martin Kocher; Garry Ceccon; Jan-Michael Werner; Anna Brunn; Martina Deckert; Whitney B Pope; Riccardo Soffietti; Emilie Le Rhun; Michael Weller; Jörg C Tonn; Gereon R Fink; Karl-Josef Langen Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300
Authors: Tyler P Robin; Robert E Breeze; Derek E Smith; Chad G Rusthoven; Karl D Lewis; Rene Gonzalez; Amanda Brill; Robin Saiki; Kelly Stuhr; Laurie E Gaspar; Sana D Karam; David Raben; Brian D Kavanagh; Sameer K Nath; Arthur K Liu Journal: J Neurooncol Date: 2018-06-16 Impact factor: 4.130
Authors: Maximilian Rauch; Daniel Tausch; Susanne Stera; Oliver Blanck; Robert Wolff; Markus Meissner; Hans Urban; Elke Hattingen Journal: J Neurooncol Date: 2021-03-24 Impact factor: 4.130
Authors: Yuanxuan Xia; Leila A Mashouf; Russell Maxwell; Luke C Peng; Evan J Lipson; William H Sharfman; Chetan Bettegowda; Kristin J Redmond; Lawrence R Kleinberg; Michael Lim Journal: Surg Neurol Int Date: 2018-07-26